nicotine has been researched along with duloxetine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Abraham, R; Bhyrapuneni, G; Bogaraju, N; Jasti, V; Mekala, VR; Mohammed, AR; Muddana, N; Nirogi, R; Palacharla, RC; Ravella, SR; Shinde, AK; Subramanian, R; Thentu, JB | 1 |
2 other study(ies) available for nicotine and duloxetine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.
Topics: Administration, Oral; Animals; Antidepressive Agents; Bridged Bicyclo Compounds; Depression; Halogenation; Humans; Male; Nicotinic Antagonists; Pyridines; Rats; Rats, Wistar; Receptors, Nicotinic | 2020 |